Magic Johnson
Showing 1–7 of 7 transcripts.
- a16z1h 5m
Inside The Life of Silicon Valley's First Athlete Investor | Magic Johnson
Magic Johnson, Chris Lyons, Earvin "Magic" Johnson, Michael Ovitz, Dr. Jerry Buss
Magic Johnson outlines the strategic transformation of sports franchises into billion-dollar assets, highlighting how ownership shifts toward equity over endorsements and leveraging high consumer demand alongside mobile streaming trends. He details a diversified investment philosophy that prioritizes cash-flow-positive sectors like healthcare infrastructure and AI, while emphasizing the critical need for athletes to build capital reserves and secure mentorship to navigate complex deal executions. Ultimately, Johnson advocates for a collaborative approach where established figures share knowledge and networks to democratize business access, enabling the next generation of athlete-entrepreneurs to capitalize on emerging markets such as women's sports and the NIL economy.
Alex Rodriguez: From MVP to CEO; Business Lessons from Warren Buffett & Magic Johnson | E1010
Alex Rodriguez, Warren Buffett, Magic Johnson, Harry Stebbings
Alex Rodriguez leverages his transformation from a performance-enhanced suspension to a disciplined investor to guide A-Rod Corp through strategic ventures in real estate and sports, including the twelve-fold return on Petro's Pace. Drawing on mentors like Magic Johnson and Warren Buffett, Rodriguez prioritizes deep expertise and "hire slow, fire fast" principles to build teams that balance aggressive deal-making with a renewed focus on fan affordability and leadership accountability. His current operations concentrate exclusively on sports and real estate sectors, aiming to lead the Minnesota Timberwolves to a championship while maintaining a corporate culture rooted in empathy and present fatherhood.
- Goldman Sachs14 min
Talks at GS – Magic Johnson On “Over-Delivering” On And Off The Court
Magic Johnson, Earvin "Magic" Johnson
Magic Johnson transitioned from leading Michigan State to an NCAA title and cultivating a legendary rivalry with Larry Bird in the NBA to a distinguished business career driven by strategic mentorship and deep market insight. Following his 1991 HIV diagnosis, he credits his 26-year survival to a regimen of mental resilience, physical training, and medication adherence, while leveraging his public platform to launch ventures like Magic Johnson Theaters and invest in the Los Angeles Sparks and Dodgers. Johnson now focuses his legacy on creating economic opportunities for people of color in urban America, prioritizing societal impact over personal wealth accumulation.
- Milken Institute1h 1m
Lunch Program | The Business of Sports
Mindy Silverstein, Jim Gray, Magic Johnson, Larry Fitzgerald, Brian France, Patrice Mosepe
A panel of prominent sports figures including Magic Johnson, Larry Fitzgerald, and Brian France discussed the critical intersection of franchise ownership, economic sustainability, and social impact in modern athletics. The conversation highlighted the economic imperatives of social media integration, the urgent need for athlete financial literacy to prevent post-career insolvency, and the ongoing debate over compensating college athletes and managing concussion risks. Furthermore, the group emphasized sports' unique capacity to drive racial reconciliation and inclusivity, citing the 1995 Rugby World Cup and current locker room dynamics as evidence of athletics serving as a catalyst for broader social cohesion.
- Milken Institute1h 2m
Immunotherapy: The Silver Bullet Against Cancer?
Dr. Jonathan Simons, Jed Wolchuk, Pam Sharma, Dr. Charles Drake, Elliot Siegel, TJ Sharp, Mary, Dr. William Coley, Jim Allison, Keith Black, Don Coffey, Magic Johnson, Tom Frye, Eleanor Roosevelt, Adlai Stevenson, Dr. Howard Sewell, Carl June, Drew Pardola
Hosted by Prostate Cancer Foundation President Dr. Jonathan Simons, a panel of leading oncologists and industry experts detailed the transformative impact of checkpoint inhibitors, which extended survival for terminal melanoma patients from months to years and triggered 20% cure rates. While the discussion highlighted expanding efficacy in lung and kidney cancers, the group identified critical barriers regarding "cold" tumors, inefficient serial trial designs, and federal funding disparities that threaten early-career research. The panelists concluded by advocating for parallel testing of combination therapies, revised FDA endpoints to accelerate approvals, and increased government investment to bridge the gap between immunological discovery and clinical application.
- Milken Institute54 min
Magic Johnson and David Ho: Winning the Battle Against AIDS (updated)
Magic Johnson, David Ho, Earvin (Magic) Johnson, Al Michaels
In 1938, President Roosevelt launched a campaign against polio that, following the 1955 introduction of the Salk vaccine and strategic public endorsements, reduced US cases by 99.9% and annual costs from $100 billion to $100 million by the turn of the millennium. Decades later, the HIV/AIDS epidemic reshaped global health through pivotal moments such as Magic Johnson's 1991 retirement announcement and Dr. David Ho's development of HAART therapy, which transformed the disease from a fatal diagnosis into a manageable chronic condition for many. Today, despite significant advances in treatment and the efforts of advocates like Bill Gates and Dr. Ho, the disease remains a critical global challenge affecting millions, particularly in sub-Saharan Africa and among specific US demographics, necessitating continued research for a vaccine and cure.
- Milken Institute58 min
Magic Johnson and David Ho: Winning the Battle Against AIDS
Magic Johnson, David Ho, Earvin (Magic) Johnson, Al Michaels
This event examines the historical parallel between the 1955 polio vaccine breakthrough and the 1991 HIV diagnosis of Magic Johnson, contrasting how celebrity advocacy and scientific innovation transformed both diseases from fatal epidemics into manageable conditions. Featuring physician Dr. David Ho and former NBA star Magic Johnson, the presentation details the shift from terminal diagnoses following the 1996 "Hiroshima" treatment breakthrough to current efforts targeting a functional cure and global eradication. The discussion concludes by analyzing persistent disparities in sub-Saharan Africa and among racial minorities in the United States while highlighting how HIV research has accelerated broader medical advancements in immunology and drug approval processes.